Stephen M. Ansell, MD, PhD, Simon Rule, MD, and Anas Younes, MD

In this segment, “New Therapies for Mantle Cell Lymphoma”, Stephen M. Ansell, MD, PhD, Simon Rule, MD and Anas Younes, MD highlight emerging trends.

Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized treatment of MCL, and the progress continues. While the approved BTK inhibitors are similar in many ways, there are some differences that may influence treatment choice. Currently, trials are studying how and when to use these agents upfront, and they are expected to become standard of care. Consequently, the use of upfront stem cell transplant is likely to decline. P53 mutations have poor prognosis in MCL, suggesting a role for allogeneic transplantation in these patients.

Share this story, choose your platform!